Pulmocide Announces Expansion of Management Team

LONDON, June 08, 2023 — Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing novel inhaled therapies for patients suffering from serious acute and chronic respiratory diseases, today announced the appointments of Matt Dallas as its Chief Financial Officer and Ashish Sagrolikar as its Chief Commercial Officer.

See the full press release here.

Scroll to Top